Physician profile
Kelli Mathew
NPI 1386962223
$3,348.75
in general payments reported to CMS, 2019-2025
41 companies · $1,715 in 2025
The $1,715 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $310 · 2021: $12.59 · 2022: $140 · 2023: $129 · 2024: $145 · 2025: $1,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666 · Travel and Lodging: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.32 |
| Travel and Lodging | $322.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $441.57 | 2025 | |
| Glaxosmithkline, LLC. | $409.09 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $297.11 | 2019-2025 | |
| Grifols USA, LLC | $282.33 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.27 | 2019-2025 | Ofev |
| Astellas Pharma US INC | $215.80 | 2019 | |
| Insmed, INC. | $212.91 | 2020-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $161.40 | 2019-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $141.99 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $111.58 | 2019-2024 | Xolair |
| Erbe USA INC | $100.00 | 2025 | Erbecryo2 |
| Takeda Pharmaceuticals U.S.A., INC. | $81.31 | 2019-2025 | Aralast, Glassia |
| Mylan Specialty L.P. | $77.02 | 2019-2023 | Yupelri |
| Tetraphase Pharmaceuticals, INC. | $51.56 | 2019 | |
| Merck Sharp & Dohme LLC | $39.44 | 2025 | Zerbaxa |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.